Evidence map›Paper›PMID 39901140›Full record

ArticleBMC cancer2025

Role of

Junjie Fan, Ke Xu, Zhangdong Jiang, Chaosheng Gan, Hao Song, Guoqiang Gao, Guojing Wang, Qiyuan Kang, Liang Luo, Zhuonan Wang and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Junjie Fan *Department of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, P.R. China.
Ke XuDepartment of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, P.R. China.
Zhangdong JiangDepartment of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, P.R. China.
Chaosheng GanDepartment of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, P.R. China.
Hao SongDepartment of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, P.R. China.
Guoqiang GaoDepartment of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, P.R. China.
Guojing WangDepartment of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, P.R. China.
Qiyuan KangDepartment of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, P.R. China.
Liang LuoDepartment of PET/CT imaging, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, P.R. China.
Zhuonan WangDepartment of PET/CT imaging, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, P.R. China.
Dalin HeDepartment of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, P.R. China.
XiaoYi DuanDepartment of PET/CT imaging, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, P.R. China.
Kaijie WuDepartment of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, P.R. China. kaijie_wu@163.com.

Funding

Key Research and Development Program of Shaanxi Province 2022SF-307the National Natural Science Foundation of China NSFC 81202014the Natural Science Foundation in Shaanxi Province 2023-JC-QN-0890
6 · The paper itself

Abstract

backgroundCytoreductive radical prostatectomy (cRP) has emerged as a promising therapeutic approach for low-volume metastatic hormone-sensitive prostate cancer (mHSPC), but the best candidates for cRP are still unknown. This study aims to explore the potential value of

methodsA total of 122 patients with primary low-volume mHSPC who underwent

resultsAmong 122 patients, 37 (30.32%) underwent systemic therapy plus cRP. The median and optimal cutoff values of the whole-body PSMA-TV were 71.68 cm

conclusionIn management of primary low-volume mHSPC, whole-body and prostate PSMA-TV evaluations based on

trial registrationRetrospectively registered.

Indexed as

Cytoreduction Surgical ProceduresPositron Emission Tomography Computed TomographyProstatectomyProstatic NeoplasmsAgedFluorine RadioisotopesHumansMaleMiddle AgedNiacinamideOligopeptidesRetrospective StudiesTumor BurdenFluorine RadioisotopesNiacinamideOligopeptidesPSMA-100718F-PSMA-1007 PET/CTCytoreductive radical prostatectomyLow-volume mHSPCNonregional lymph node metastasesPSMA-TV

Identifiers

PMID39901140
PMCPMC11789373

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.